Enoximone (trade name Perfan) is an intravenous, selective phosphodiesterase 3 (PDE3) inhibitor used primarily to treat acute, severe congestive heart failure and as a bridge for patients awaiting cardiac transplantation.
It acts as an inotropic vasodilator, improving cardiac output and decreasing heart workload, often used when other therapies fail.
Used for acute,decompensated heart failure, especially where cardiac output is reduced and filling pressures are increased.
It is used for short-term management, sometimes as a bridge to heart transplant or in patients dependent on intravenous inotropes.
Mechanism of Action: As a PDE3 inhibitor, it increases cyclic adenosine monophosphate (cAMP) in cardiac and vascular smooth muscle cells, resulting in increased heart contractility (positive inotropy) and reduced peripheral resistance (vasodilation).
Typically administered intravenously (IV), with a loading dose of 90 mg/kg/min over 10–30 minutes, followed by a maintenance infusion of 5–20mg/kg/min.
Adverse Effects: Common side effects include cardiac arrhythmias (ventricular tachycardia), hypotension, nausea, vomiting, and diarrhea.
it is not approved for use in the United States.
Indications and dose: Intravenous infusion Adults: Initially 90 micrograms/kg/minute, dose to be given over 10–30 minute…